Focusing on innovation, unveiling new vision creation.

Link to: News

News

Link to: Projects

Projects

Link to: ESG-Sustainability

ESG

News

The Phase II clinical trial of myopia control treatment has enrolled a total of 112 participants. Approximately 80% of the subjects have successfully completed one year of the trial. The last subject is expected to complete the study medication administration by December 31, 2026, marking the completion of the treatment phase. The trial is progressing smoothly and in line with expectations.

Sunhawk Vision Mandated by Global Mega-Pharma Titans for Exclusive One-on-One Closed-Door Summits at BIO 2026 to Leverage Strategic Licensing and Equity Bids for SHJ002 Platform.

The Phase II clinical trial of myopia control treatment has enrolled a total of 140 participants across sites in the United States and Taiwan. As of May 29, 50% subjects of this trial has successfully completed the one-year treatment protocol and the remaining 50% subjects are scheduled to complete all treatment by December 2026. The study is scheduled for unblinding in the first quarter of 2027.

Sunhawk Vision Announces SHJ002 Phase 2 DED Results in NIH-Indexed Clinical Therapeutics: Breakthrough Efficacy in Corneal Repair to Redefine Global Market Landscape

The Phase II clinical trial of myopia control treatment has enrolled a total of 140 participants across sites in the United States and Taiwan. As of April 2, 25 subjects have successfully completed the one-year treatment protocol. The study is scheduled for unblinding in the first quarter of 2027.

The company has successfully completed the interim review by the Data Monitoring Committee (DMC) for its Phase II clinical trial of childhood myopia treatment.

FDA approved the Phase-III clinical trial for Dry Eye Disease.

Sunhawk Vision received the approval of Australia patent for the company’s novel eye drops, SHJ002, in treating ocular surface diseases (including dry eye disease).

Sunhawk Vision submitted the request to U.S. FDA for Orphan Drug Designation (ODD) for SHJ002 ophthalmic solution in treating recurrent corneal erosion in patients with Sjogren’s syndrome.

The eye drop SHJ002 for the treatment of dry eye disease has completed the submission of the Investigational New Drug (IND) application for phaseIII clinical trials to the U.S. FDA.

The Phase II clinical trial of myopia control treatment has enrolled a total of 112 participants. Approximately 80% of the subjects have successfully completed one year of the trial. The last subject is expected to complete the study medication administration by December 31, 2026, marking the completion of the treatment phase. The trial is progressing smoothly and in line with expectations.

Sunhawk Vision Mandated by Global Mega-Pharma Titans for Exclusive One-on-One Closed-Door Summits at BIO 2026 to Leverage Strategic Licensing and Equity Bids for SHJ002 Platform.

The Phase II clinical trial of myopia control treatment has enrolled a total of 140 participants across sites in the United States and Taiwan. As of May 29, 50% subjects of this trial has successfully completed the one-year treatment protocol and the remaining 50% subjects are scheduled to complete all treatment by December 2026. The study is scheduled for unblinding in the first quarter of 2027.

Sunhawk Vision Announces SHJ002 Phase 2 DED Results in NIH-Indexed Clinical Therapeutics: Breakthrough Efficacy in Corneal Repair to Redefine Global Market Landscape

The Phase II clinical trial of myopia control treatment has enrolled a total of 140 participants across sites in the United States and Taiwan. As of April 2, 25 subjects have successfully completed the one-year treatment protocol. The study is scheduled for unblinding in the first quarter of 2027.

The company has successfully completed the interim review by the Data Monitoring Committee (DMC) for its Phase II clinical trial of childhood myopia treatment.

FDA approved the Phase-III clinical trial for Dry Eye Disease.

Sunhawk Vision received the approval of Australia patent for the company’s novel eye drops, SHJ002, in treating ocular surface diseases (including dry eye disease).

Sunhawk Vision submitted the request to U.S. FDA for Orphan Drug Designation (ODD) for SHJ002 ophthalmic solution in treating recurrent corneal erosion in patients with Sjogren’s syndrome.

The eye drop SHJ002 for the treatment of dry eye disease has completed the submission of the Investigational New Drug (IND) application for phaseIII clinical trials to the U.S. FDA.

最新消息

Sunhawk Vision submitted the request to U.S. FDA for Orphan Drug Designation (ODD) for SHJ002 ophthalmic solution in treating recurrent corneal erosion in patients with Sjogren’s syndrome.

Read more

The eye drop SHJ002 for the treatment of dry eye disease has completed the submission of the Investigational New Drug (IND) application for phaseIII clinical trials to the U.S. FDA.

Read more

Sunhawk Vision received the approval of Japanese patent for the company’s novel eye drops, SHJ002, in treating ocular surface diseases (including dry eye disease).

Read more

Sunhawk Vision has signed a contract with a U.S. pharmaceutical company with 30 years of manufacturing experience and is scheduled to manufacture clinical trial ophthalmic solution in the United States in August 2025.

Read more

The clinical data on the Phase-II trial for corneal erosion in patients with Sjogren’s syndrome (NCT06381986) were locked on May 5, 2025. The data were unblinded and under statistical analysis.

Read more

Sunhawk Vision has completed all subject assessments in its Phase II clinical trial evaluating the treatment of corneal erosion in patients with Sjogren’s syndrome.

Read more

Sunhawk Vision has been registration as an Emerging Stock approved by the Taipei Exchange (OTC) Trading Center, meanwhile trading will commence from March 10, 2025.

Read more

Taipei Office

© Copyright – Sunhawk Vision Biotech, Inc.

design by Morcept

© Copyright – Sunhawk Vision Biotech, Inc.
design by Morcept